BioSpace News Archive

INmune Bio, Inc. announced that XPro™, the Company’s selective DN-TNF inhibitor candidate for the treatment of Alzheimer’s disease, treatment resistant depression, and other neurological diseases where neuroinflammation is implicated, has been found to decrease multiple species of Phospho Tau and improve neuroimaging biomarkers of myelination in patients with AD.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company committed to being the leader in responsible pain management, announced that management will participate in the following investor conferences during the month of September

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Phase 3 PANTHER (Pevonedistat-3001) study did not achieve pre-defined statistical significance for the primary endpoint of event-free survival (EFS).

Minnesota based Laplace Interventional, a medical device company developing a transcatheter tricuspid valve technology, announced today that it has closed on its Series A financing led by a non-disclosed major strategic investor along with a significant investment from ShangBay Capital, an early stage medical device investor as well as other investors including Mayo Clinic.

From Parkinson’s to schizophrenia and depression, Modality’s multimodal solution – the first of its kind – is being used by leading research institutions globally to monitor, diagnose, and expedite the treatment of patients in clinic and remotely.

Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it has initiated its submission to the U.S. Food and Drug Administration (FDA) for the evaluation of a booster dose of the Moderna COVID-19 vaccine (mRNA-1273) at the 50 µg dose level.

Oyster Point Pharma, Inc. announced that the Compensation Committee of its Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 177,000 shares of common stock to 110 new employees, pursuant to the Oyster Point Pharma, Inc., 2021 Inducement Incentive Plan.

OSE Immunotherapeutics (ISIN: FR0012127173) today announced it will present at the H.C. Wainwright 23 r d Annual Global Investment Conference. The conference is being held virtually on September 13 – 15, 2021.

Transgene announces its participation in the launch of PERSIST-SEQ, a new international consortium of academic and industrial leaders in the field of cancer research.

MicroMGx, Inc., a life sciences company dedicated to making high-throughput natural product discovery achievable, today announced an expanded agreement focused on accelerating natural products discovery with pure-play global agriculture company Corteva Agriscience